VaccinesStudies updated this monthAluminum in vaccines — what aren’t parents being told?
What do Natural Therapy Specialists write?
The amount of aluminum in vaccines for infants exceeds the permissible limits by 2,500 times.
Aluminum from vaccines is said to cause chronic brain inflammation and behavioral and eating disorders.
Aluminum is said to be highly toxic to the islets of Langerhans, and damage to or destruction of them is said to lead to diabetes.
Aluminum-containing vaccine adjuvants are linked to a possible causal relationship with the rising incidence of ASD.
Aluminum may intensify mercury’s neurotoxicity, and injecting it into a body burdened with mercury may result in a serious vaccine reaction.
Aluminum is listed as a substance in vaccines that Jerzy Zięba considers more dangerous than mercury.
The average doctor is said not to know the true composition of vaccines.
Jerzy Jaśkowski cites the view that aluminum is a neurotoxin that damages the brain and asks why it is injected into children.
Exposure to heavy metals, including aluminum, is said to be linked to diabetes.
What does scientific research from PubMed · Europe PMC say?
We selected 8 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 4 148.
Aim of the study: Aluminum salts have been used as adjuvants in vaccines for nearly a century, enhancing the immune response to purified antigens and ensuring durable protection against serious infectious diseases. Despite their longstanding record of safety and effectiveness, aluminum adjuvants have become a focus of public concern, with claims linking them to developmental, neurologic, allergic, and autoimmune diseases.
Results: Large-scale clinical and epidemiologic studies consistently demonstrate no association between aluminum-adjuvanted vaccines and autism spectrum disorder, neurotoxicity, allergic disease, or autoimmune disease. Clinically, vaccines adjuvanted solely with aluminum salts generally do not result in systemic reactogenicity, although local reactions are common. Collectively, the evidence strongly supports the safety of aluminum adjuvants and their necessity in certain vaccines. Clinicians can reassure caregivers that aluminum-containing vaccines provide clear benefits, with risks largely limited to transient local reactions and no systemic toxicity signal in large clinical and epidemiologic studies.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Aluminum is used as an adjuvant in nonlive vaccines administered in early childhood. Concerns persist about potential associations between vaccination with aluminum-adsorbed vaccines and increased risk for chronic autoimmunity, atopy or allergy, and neurodevelopmental disorders. Large-scale safety data remain limited.
Results: Cumulative aluminum exposure from vaccination during the first 2 years of life was not associated with increased rates of any of the 50 disorders assessed. For groups of combined outcomes, adjusted hazard ratios per 1-mg increase in aluminum exposure were 0.98 (95% CI, 0.94 to 1.02) for any autoimmune disorder, 0.99 (CI, 0.98 to 1.01) for any atopic or allergic disorder, and 0.93 (CI, 0.90 to 0.97) for any neurodevelopmental disorder. For most individually analyzed outcomes, the upper bounds of the 95% CIs were incompatible with relative increases greater than 10% or 30%. This nationwide cohort study did not find evidence supporting an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders associated with early childhood exposure to aluminum-adsorbed vaccines.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: French people have never been so wary about vaccines. The use of aluminum salts in vaccine adjuvants to enhance effectiveness is one of the major reasons for this lack of confidence.
Results: Aluminum levels in biological media of vaccinated subjects are not different from those of unvaccinated subjects. This is consistent with the very small amount of aluminum contained in one dose of vaccine. Indirect toxicity of aluminum was suggested to explain macrophagic myofasciitis in humans in 2011, a disease that could be mediated by an autoimmune/autoinflammatory mechanism. This hypothesis has recently been refuted in a large pharmaco-epidemiological study proving that aluminum-containing adjuvants of vaccines are not responsible for this autoimmune/autoinflammatory syndrome.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Aluminum is a ubiquitous element that is released naturally into the environment via volcanic activity and the breakdown of rocks on the earth's surface. Exposure of the general population to aluminum occurs primarily through the consumption of food, antacids, and buffered analgesics.
Results: We updated the analysis of Keith et al. [1] with a current pediatric vaccination schedule [2]; baseline aluminum levels at birth; an aluminum retention function that reflects changing glomerular filtration rates in infants; an adjustment for the kinetics of aluminum efflux at the site of injection; contemporaneous MRLs; and the most recent infant body weight data for children 0-60 months of age [3]. Using these updated parameters we found that the body burden of aluminum from vaccines and diet throughout an infant's first year of life is significantly less than the corresponding safe body burden of aluminum modeled using the regulatory MRL. We conclude that episodic exposures to vaccines that contain aluminum adjuvant continue to be extremely low risk to infants and that the benefits of using vaccines containing aluminum adjuvant outweigh any theoretical concerns.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Aluminum in the form of aluminum hydroxide, aluminum phosphate or alum has been commonly used as an adjuvant in many vaccines licensed by the US Food and Drug Administration. Chapter 21 of the US Code of Federal Regulations [610.15(a)] limits the amount of aluminum in biological products, including vaccines, to 0.85 mg/dose.
Results: Clinical studies have demonstrated that aluminum enhances the antigenicity of some vaccines such as diphtheria and tetanus toxoids. Moreover, aluminum-adsorbed diphtheria and tetanus toxoids are distinctly more effective than plain fluid toxoids for primary immunization of children. There is little difference between plain and adsorbed toxoids for booster immunization. Aluminum adjuvants have a demonstrated safety profile of over six decades; however, these adjuvants have been associated with severe local reactions such as erythema, subcutaneous nodules and contact hypersensitivity.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: This study evaluates the functional capacity of CD4+ and CD8+ terminally-differentiated effector (TEMRA), central memory (TCM), and effector memory (TEM) cells obtained from the volunteers vaccinated with an aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac). The volunteers were followed for T cell immune responses following the termination of a randomized phase III clinical trial.
Results: More than 73% (after a short-term) and 62% (after an intermediate-term) of the vaccinated individuals harbored TCM and/or TEM cells that responded to S1-loaded mDCs by secreting IFN-γ. The expression of CD25, CD38, 4-1BB, PD-1, and CD107a indicated a modulation in the memory T cell subsets. Especially on day 120, PD-1 was upregulated on CD4+ TEMRA and TCM, and on CD8+ TEM and TCM cells; accordingly, proliferation and IFN-γ secretion capacities tended to decline after 4 months. In conclusion, the combination of inactivated whole-virion particles with aluminum adjuvants possesses capacities to induce functional T cell responses.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: We systematically reviewed and summarized studies focusing on Bharat Biotech's Whole Virion Inactivated Corona Virus Antigen BBV152 (Covaxin), which is India's indigenous response to fighting the SARS-CoV-2 pandemic. Studies were searched for data on the efficacy, immunogenicity, and safety profile of BBV152.
Results: There was some evidence of coverage against the Alpha, Beta, and Delta variants. However, neither Covaxin nor Covishield showed sufficient protection against the Omicron variant. Two studies reported super-additive results on mixing Covaxin with Covishield. Further exploration of heterologous prime-boost vaccination with a combination of an inactivated vaccine and an adenoviral vector-based vaccine for tackling future variants may be beneficial.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Avian H7N9 influenza viruses possess a potential pandemic threat to public health worldwide, and have caused severe infection and high mortality in humans. A series of clinical trials of H7N9 vaccines have been completed. Meta-analyses need to be performed to assess the immunogenicity and safety of H7N9 vaccines.
Results: For non-adjuvanted H7N9 vaccines, high dose formulations induced limited immunogenicity and increased the risk of local and systemic adverse events, simultaneously. For adjuvanted H7N9 vaccines, on the one hand, ISCOMATRIX, MF59, AS03 and aluminium adjuvants applied in H7N9 vaccines could improve immune responses effectively, and non-aluminium adjuvants had superior performance in saving vaccine dose; on the other hand, aluminium adjuvant had the advantages of safety amongst these adjuvants applied in H7N9 vaccines. H7N9 influenza vaccines with adjuvant might represent the optimal available option in an influenza pandemic, at present.
“Not stated” does not mean nobody paid — the database does not always record it.
What do orthomolecular medicine doctors write?
Sources (17)
- Hubert Czerniak — Wyleczyć nieuleczalne – autyzm
- Piotr Witczak — Dlaczego rtęć należy uważać za główną przyczynę autyzmu?
- Jerzy Zięba — Szczepienia i Wakefield
- Jerzy Zięba — Szczepionkowe eldorado
- Jerzy Jaśkowski — Autyzm – czyli jak nas podstępnie uszkadzają i okradają
- Jerzy Jaśkowski — Przechytrzyć cukrzycę. Część 1
- The Role and Safety of Aluminum Adjuvants in Childhood Vaccines. · Pediatrics 2026
- Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood : A Nationwide Cohort Study. · Ann Intern Med 2025
- Aluminum and vaccines: Current state of knowledge. · Med Mal Infect 2020
- Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. · Vaccine 2011
- Aluminum salts in vaccines--US perspective. · Vaccine 2002
- Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. · Sci Rep 2023
- Inactivated vaccine Covaxin/BBV152: A systematic review. · Front Immunol 2022
- Comparative effectiveness of H7N9 vaccines in healthy individuals. · Hum Vaccin Immunother 2019
- Orthomolecular Medicine News Service — VACCINE ADJUVANTS AND EXCIPIENTS: Know what else comes through the needle?
- Orthomolecular Medicine News Service — Orthomolecular Treatment for Adverse Effects of Human Papilloma Virus (HPV) Vaccine
- Orthomolecular Medicine News Service — Born Defenseless: Why Infant Liver Maturity May Be the Missing Piece in Understanding Vaccine Safety, SIDS, and NDDs
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.